article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

article thumbnail

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

Bio Pharma Dive

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

Licensing 265
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmaceutical Technology

Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health.

Hormones 263
article thumbnail

TherapeuticsMD and Mayne sign product licensing agreements

Pharmaceutical Technology

Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US.

Licensing 130
article thumbnail

Takeda signs licensing agreement with HUTCHMED for fruquintinib

Pharmaceutical Technology

It was commercially launched in the country in the same year under ELUNATE brand name. The post Takeda signs licensing agreement with HUTCHMED for fruquintinib appeared first on Pharmaceutical Technology. The China National Medical Products Administration (NMPA) approved fruquintinib for marketing in September 2018.

Licensing 130
article thumbnail

China’s NMPA grants priority review status for Ocumension’s Zerviate NDA

Pharmaceutical Technology

The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Zerviate, 0.24% was compared to emedastine difumarate ophthalmic solution, 0.05%, an antihistamine, which is marketed under undeb Emadine brand name.

Licensing 162
article thumbnail

Plant Veda Receives License from CFIA to Produce Branded Products at New Facility

BioTech 365

Plant Veda Receives License from CFIA to Produce Branded Products at New Facility Plant Veda Receives License from CFIA to Produce Branded Products at New Facility VANCOUVER, British Columbia–(BUSINESS WIRE)–Plant Veda Foods Ltd. CSE:MILK) (the “Company” or “Plant Veda”), an … Continue reading →